Professor   Michael Chan , Lead Scientist at C2i and CEO of C2iTech ,   was featured on RTHK's "Under the Sun" (太陽底下新鮮事) radio show, diving deep into the fascinating realm of organoid development! From lab breakthroughs to real-world impacts on medicine: https://www.rthk.hk/radio/radio1/programme/underthesun

We are delighted to share that C2iTech has been invited to attend the HKU Innovation Week 2025 and the TSSSU Ceremony! 🎉 As proud recipients for the 2024/2025 and 2025/2026 cycles, we look forward to showcasing our innovations and connecting with fellow leaders in technology and entrepreneurship. More info about the HKU Innovation Week: https://tec.hku.hk/innovation-week/ Join us as we drive the future of innovation!

The InnoHK Centre for Immunology & Infection Limited (C2i) and its spin-off C2iTech Limited have signed a Memorandum of Understanding (MOU) with Guangzhou Jingke Biotech Co., Ltd. and Shenzhen Jingke Biotech Co., Ltd. to advance patient-derived organoid (PDO) technologies for personalized oncology. The signing parties were represented by Professor Leo Poon , Managing Director, C2i; Professor Michael Chan , CEO, C2iTech; Mr. Sheng Li, Chairman, Jingke Biotech Group, and Profes

Job Reference Number: C2i117-RP3 The Centre for Immunology & Infection (C2i) uses novel technology platforms for biomarker discovery and...